At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 13 enrolled
Drug / intervention
Daratumumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia
In Brief
A Phase 2 clinical trial evaluating Daratumumab for Waldenström Macroglobulinemia. Completed, enrolled 13 participants across 5 sites.
Detailed Summary
This research study is studying Daratumumab as a possible treatment for Waldenström Macroglobulinemia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsWaldenström Macroglobulinemia
CountriesUnited States
CollaboratorsJanssen, LP
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJun 2017
Enrollment StartNov 2017
Primary CompletionJan 2021
Study CompletionDec 2021
TodayJul 2026
First PostedJun 14, 2017
Enrollment StartNov 27, 2017
Primary CompletionJan 31, 2021
Study CompletionDec 31, 2021
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 9.0 years ago
Interventions
Daratumumabdrug
Daratumumab is a monoclonal human antibody. Daratumumab has shown the ability to slow or stop the growth of cells that have CD38 on the cell surface when tested in laboratories